Loading...
  • PBSC
  • Evaluate the effectiveness of TXA127 in accelerating the time to initial platelet recovery following PBSC transplant with a limited number of CD34+ cells, defined as CD34+ cell concentrations ≥1.5 x 106 and ≤5.0 x 106 CD34+ cells/kg. (clinicaltrials.gov)
  • rescue
  • Consolidation therapy followed by stem cell rescue repeats every 28 days for 3 courses (C) and 3D-CRT to the brain (and the spine if needed) 5 days a week for 5-6 weeks (R), the order of which depends on patient age, in the absence of disease progression or unacceptable toxicity. (clinicaltrials.gov)
  • high dose
  • Determine the kinetics of T- and B- cell immune reconstitution after a combination of timed plasmapheresis, high dose cyclophosphamide and total lymphoid irradiation, and posttransplant immunosuppression with cyclosporine in these patients. (clinicaltrials.gov)
  • Transplants
  • To make sure that all of the tumor cells are destroyed, patients in this study will undergo two separate transplants using two different preparative regimens. (knowcancer.com)
  • Researchers are also evaluating how well the blood stem cells grow in the patient's body, and whether CliniMACS T-cell depleted transplants can prevent GvHD. (mskcc.org)
  • mobilize
  • 4-7 Cytokines mobilize long-term culture-initiating cells (LTC-IC) and young colony-forming unit-spleen (CFU-S) with high proliferative potential into circulation. (bloodjournal.org)
  • tumor cells
  • Patients who benefit most from this treatment are those whose marrow is infiltrated with tumor cells or who have hypoplastic marrows due to extensive prior chemo- and/or radiotherapy [8-and those who might not tolerate marrow harvests under general anesthesia [6, (springer.com)
  • vivo
  • Beginning 28-120 days later, patients eligible for in vivo selection after detection of gene-marked cells receive O6-benzylguanine IV over 1 hour and carmustine IV over 3 hours on days 14, 28, and then monthly until completion of therapy. (clinicaltrials.gov)
  • 500 cells/uL receive up to 2 courses of structured treatment interruption without undergoing in vivo selection. (clinicaltrials.gov)